Clinical Trials

50 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03783949 2025-06-11

EUDARIO

122 enrolled 23 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01962948 2024-03-26

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Terminated

12 enrolled 8 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

28 enrolled

Esophagogastric Cancer

NCT01579994 2020-12-30

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Other solid neoplasmThoracic

13 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

NCT01590160 2019-11-13

MESO-02

Phase 1/2 Completed

27 enrolled

Lung Cancer - Malignant Pleural Mesothelioma

NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Phase 1/2 Terminated

133 enrolled 10 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

NCT02389751 2019-07-24

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

3 enrolled

Esophageal Neoplasms

NCT02008877 2019-05-15

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Phase 1/2 Completed

20 enrolled 20 charts

Sarcoma

Sarcoma, Neurofibrosarcoma

NCT01173523 2019-04-16

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

25 enrolled 8 charts

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT01200238 2018-10-18

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

17 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT01270880 2018-09-18

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

18 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

9 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT01665937 2018-04-25

STA-9090 in Patients With Advanced Hepatocellular Cancer

16 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02261805 2018-04-23

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Phase 1/2 Terminated

11 enrolled 7 charts

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Terminated

3 enrolled 7 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT02334319 2016-07-26

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Phase 1 Terminated

3 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02637375 2016-05-30

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Phase NA Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01554969 2016-02-22

Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

16 enrolled

Rectal Neoplasms

NCT01111838 2015-11-20

Clinical and Translational Study of STA-9090

20 enrolled 6 charts

Colonic Neoplasms, Rectal Neoplasms

NCT01273896 2015-11-20

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

22 enrolled 6 charts

Breast Neoplasms

NCT01485835 2015-10-12

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

8 enrolled

Plasma cell

Multiple Myeloma

NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Phase 2 Withdrawn

Genitourinary

Adenocarcinoma of the Prostate

NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Phase 2 Terminated

15 enrolled 9 charts